Onco-Innovations to Chair Colorectal Cancer Canada Precision Oncology Forum Driving the Future of Cancer Care
Onco-Innovations (OTCQB:ONNVF) announced that its subsidiary, Inka Health Corp., will chair and lead the fourth roundtable of Colorectal Cancer Canada's (CRC) Catalysts: Innovating for Tomorrow Series this fall. The virtual event will focus on data innovation and digital trust in oncology.
The roundtable will be chaired by Dr. Paul Arora, with expert speakers including Dr. Steve Jones from BC Cancer, Dr. Winson Cheung from the University of Calgary, and Inka Health Co-Founder Alind Gupta. The discussion will explore the integration of artificial intelligence, secure data sharing, and the application of emerging data sources in precision medicine.
Onco-Innovations (OTCQB:ONNVF) ha comunicato che la sua controllata Inka Health Corp. guiderà e modererà il quarto tavolo di Colorectal Cancer Canada (CRC) Catalysts: Innovating for Tomorrow Series previsto per questo autunno. l'evento virtuale si concentrerà sull'innovazione dei dati e sulla fiducia digitale nell'oncologia.
Il tavolo sarà presieduto dal Dott. Paul Arora, con relatori esperti tra cui Dott. Steve Jones di BC Cancer, Dott. Winson Cheung dell'Università di Calgary e il co-fondatore di Inka Health Alind Gupta. La discussione esplorerà l'integrazione dell'intelligenza artificiale, la condivisione sicura dei dati e l'applicazione di nuove fonti di dati in medicina di precisione.
Onco-Innovations (OTCQB:ONNVF) anunció que su subsidiaria, Inka Health Corp., presidirá y dirigirá la cuarta mesa redonda de CRC Catalysts: Innovating for Tomorrow Series de Colorectal Cancer Canada (CRC) este otoño. El evento virtual se enfocará en la innovación de datos y la confianza digital en oncología.
La mesa será presidida por el Dr. Paul Arora, con ponentes expertos que incluirán al Dr. Steve Jones de BC Cancer, el Dr. Winson Cheung de la University of Calgary y Alind Gupta, cofundador de Inka Health. La discusión explorará la integración de la inteligencia artificial, el intercambio seguro de datos y la aplicación de fuentes de datos emergentes en la medicina de precisión.
Onco-Innovations (OTCQB:ONNVF)은 자회사 Inka Health Corp.가 올해 가을 CRC의 Catalysts: Innovating for Tomorrow Series의 네 번째 라운드테이블을 주재하고 이끈다고 발표했습니다. 이번 가상 행사는 데이터 혁신과 종양학에서의 디지털 신뢰에 초점을 맞출 것입니다.
라운드테이블은 Dr. Paul Arora가 주재하며, BC Cancer의 Dr. Steve Jones, 캐나다 캘거리 대학교의 Dr. Winson Cheung, 그리고 Inka Health의 공동 설립자 Alind Gupta가 연사로 참여합니다. 논의는 인공지능의 통합, 안전한 데이터 공유, 그리고 정밀의학에서의 새로운 데이터 소스의 적용을 탐구할 것입니다.
Onco-Innovations (OTCQB:ONNVF) a annoncé que sa filiale, Inka Health Corp., présidera et dirigera la quatrième table ronde de la série Catalysts: Innovating for Tomorrow Series de CRC (Colorectal Cancer Canada) cet automne. L'événement virtuel se concentrera sur l'innovation des données et la confiance numérique en oncologie.
La table sera présidée par le Dr Paul Arora, avec des intervenants experts dont le Dr Steve Jones de BC Cancer, le Dr Winson Cheung de l'Université de Calgary et le co-fondateur d'Inka Health Alind Gupta. La discussion explorera l'intégration de l'intelligence artificielle, le partage sécurisé des données et l'application de sources de données émergentes en médecine de précision.
Onco-Innovations (OTCQB:ONNVF) gab bekannt, dass ihre Tochtergesellschaft Inka Health Corp. die vierte Roundtable-Veranstaltung von CRC Catalyst: Innovating for Tomorrow Series in diesem Herbst leiten und moderieren wird. Die virtuelle Veranstaltung wird sich auf Dateninnovation und digitales Vertrauen in der Onkologie konzentrieren.
Der Roundtable wird von Dr. Paul Arora geleitet, mit Expertenrednern u. a. Dr. Steve Jones von BC Cancer, Dr. Winson Cheung von der University of Calgary und dem Mitgründer von Inka Health Alind Gupta. Die Diskussion wird die Integration von künstlicher Intelligenz, sicheren Datenaustausch und die Anwendung aufkommender Datenquellen in der Personalisierten Medizin beleuchten.
أعلنت شركة Onco-Innovations (OTCQB:ONNVF) أن شركتها التابعة Inka Health Corp. ستترأس وتقود الجولة الرابعة من سلسلة Catalysts: Innovating for Tomorrow Series لـ CRC (Colorectal Cancer Canada) هذا الخريف. سيُركَّز الحدث الافتراضي على ابتكار البيانات والثقة الرقمية في علم الأورام.
سيترأس الدكتور بول أوروارا الجلسة، مع متحدثين خبراء من بينهم الدكتور ستيف جونز من BC Cancer، الدكتور ونسون تشيونغ من جامعة كالغري، والمؤسس المشارك لشركة Inka Health أليند غوبتا. ستبحث المناقشة في دمج الذكاء الاصطناعي وتبادل البيانات بشكل آمن وتطبيق مصادر البيانات الناشئة في الطب الدقيق.
Onco-Innovations（OTCQB:ONNVF）宣布，其子公司 Inka Health Corp. 将主持并领导 CRC（Colorectal Cancer Canada）Catalysts: Innovating for Tomorrow Series 的第四场圆桌讨论，计划于今年秋季举行。此次线上活动将聚焦数据创新与肿瘤学领域的数字信任。
圆桌将由 Paul Arora 博士 主持，发言嘉宾包括 BC Cancer 的 Steve Jones 博士、卡尔加里大学的 Winson Cheung 博士，以及 Inka Health 的联合创始人 Alind Gupta。讨论将探讨人工智能的整合、数据的安全共享，以及新兴数据源在精准医疗中的应用。
- None.
- None.
VANCOUVER, BC / ACCESS Newswire / September 12, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H)(WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company")is pleased to announce that its subsidiary, Inka Health Corp. ("Inka Health" or "Inka"), will chair and lead the fourth roundtable of Colorectal Cancer Canada's (CRC) Catalysts: Innovating for Tomorrow Series, a virtual event expected to take place this fall, which will focus on data innovation and digital trust in oncology. The role reflects Onco-Innovations growing involvement in guiding national discussions on areas that are becoming central to the evolution of cancer care for patients and health systems alike.
In leading this roundtable, Onco-Innovations will help guide discussions on the integration of artificial intelligence, secure data sharing, and digital trust in oncology. The session will also explore how emerging data sources, including patient support programs and synthetic datasets, can be applied to advance precision medicine globally. These themes are increasingly relevant as healthcare systems seek practical ways to harness new technologies while maintaining patient confidence and ensuring measurable improvements in cancer care.
The roundtable will be chaired by Inka Health Co-Founder Dr. Paul Arora, with Dr. Steve Jones, Senior Scientific Advisor to Onco-Innovations and a Director at the Genome Sciences Centre at BC Cancer, Dr. Winson Cheung, Full Professor of Medicine and Oncology at the University of Calgary and advisor to Onco-Innovations, and Inka Health Co-Founder Alind Gupta serving as expert speakers. Their participation reflects the calibre of leadership driving this initiative convening top-tier experts and stakeholders from across the oncology ecosystem. This engagement strengthens Onco-Innovations capacity to translate technological expertise into meaningful partnerships, policy influence, and market opportunities in the rapidly expanding field of AI-enabled healthcare.
"The real challenge in oncology is not generating more data, but creating the trust, interoperability, and intelligence that allow those data to actually improve care. We see opportunities to build systems that respect patients, empower clinicians, and accelerate research in ways that markets and health systems alike can measure. That is the conversation we want to advance at this roundtable," stated Paul Arora, Co-Founder of Inka Health.
The CRC Catalysts: Innovating for Tomorrow Roundtable Series is a new program developed by Colorectal Cancer Canada that builds upon ten years of earlier roundtable initiatives and aims to accelerate progress in colorectal cancer research and care by mirroring the "Cancer Moonshot" objectives and compressing a decade of progress into five years1. The series consists of seven themed conversations beginning this fall, each involving panels of expert stakeholders including clinicians, researchers, patient advocates, policymakers, and industry leaders who will address critical topics such as data innovation and digital trust2. By engaging in this initiative Onco-Innovations reinforce their commitment to advancing precision medicine and contributing to a national dialogue focused on innovation in cancer care.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
About Inka Health
Inka Health is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI. Its proprietary platform, SynoGraph, leverages AI-powered causal inference to identify which cancer patients are most likely to respond to specific treatments, advancing precision medicine. By integrating diverse multimodal medical data, including genomics, transcriptomics, and proteomics, SynoGraph uncovers hidden insights that can optimize treatment decisions and clinical trial design. With this cutting-edge technology, Inka Health aims to help pharmaceutical companies accelerate drug development, reduce trial failures, and bring life-saving therapies to market faster.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
When will Onco-Innovations (ONNVF) chair the CRC Catalysts roundtable event?
Who are the key speakers at the Onco-Innovations (ONNVF) CRC roundtable?
What topics will be discussed at the Onco-Innovations (ONNVF) CRC roundtable?
What is the goal of CRC's Catalysts: Innovating for Tomorrow Series?
